News Column

New Findings on Immunotherapy from University of California Summarized

June 2, 2014

By a News Reporter-Staff News Editor at Clinical Oncology Week -- Investigators publish new report on Biotechnology. According to news originating from San Francisco, California, by NewsRx correspondents, research stated, "Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352: 987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in clinical outcomes are modest, in no small part due to tumor-induced immunosuppressive mechanisms that promote immune escape and immuno-resistance."

Our news journalists obtained a quote from the research from the University of California, "Immunotherapeutic strategies aimed at bolstering the immune response while neutralizing immunosuppression will play a critical role in improving treatment outcomes for glioblastoma patients. In vivo murine models of glioma provide an invaluable resource to achieving that end, and their use is an essential part of the preclinical workup for novel therapeutics that need to be tested in animal models prior to testing experimental therapies in patients."

According to the news editors, the research concluded: "In this article, we review five contemporary immunocompetent mouse models, GL261 (C57BL/6), GL26 (C57BL/6) CT-2A (C57BL/6), SMA-560 (VM/Dk), and 4C8 (B6D2F1), each of which offer a suitable platform for testing novel immunotherapeutic approaches."

For more information on this research see: Immunocompetent murine models for the study of glioblastoma immunotherapy. Journal of Translational Medicine, 2014;12():1-10. Journal of Translational Medicine can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central -; Journal of Translational Medicine -

The news correspondents report that additional information may be obtained from T. Oh, University of California, Dept. of Neurol Surg, San Francisco, CA 94143, United States. Additional authors for this research include S. Fakurnejad, E.T. Sayegh, A.J. Clark, M.E. Ivan, M.Z. Sun, M. Safaee, O. Bloch, C.D. James and A.T. Parsa (see also Biotechnology).

Keywords for this news article include: Biotechnology, Oncology, California, Glioblastoma, San Francisco, United States, Immunotherapy, Immunomodulation, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Clinical Oncology Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters